loading...| Preferred Name |
Daptomycin |
|
| Synonyms |
N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone Cubicin DAPTOMYCIN Daptomycin LY146032 daptomycin |
|
| Definitions |
A semi-synthetic cyclic lipopeptide antibiotic isolated form the bacterium Streptomyces roseosporus with broad-spectrum antibiotic activity against Gram-positive bacteria. Daptomycin has a distinct mechanism of action, in which it binds to bacterial membrane and causes rapid depolarization of the cell membrane due to calcium-dependant potassium efflux; the loss of membrane potential leads to inhibition of DNA, RNA and protein synthesis, resulting in bacterial cell death. This agent does not penetrate the outer membrane of gram-negative bacteria. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C47470 |
|
| ALT_DEFINITION |
A drug used to treat certain bacterial skin and bloodstream infections in adults. Cubicin is also being studied in the treatment of fever and neutropenia (an abnormal decrease in the number of neutrophils, a type of white blood cell) in patients with cancer. It is a type of antibiotic. |
|
| CAS_Registry |
103060-53-3 |
|
| CHEBI_ID |
CHEBI:600103 |
|
| Chemical_Formula |
C72H101N17O26 |
|
| code |
C47470 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 |
|
| Contributing_Source |
CTRP FDA |
|
| DEFINITION |
A semi-synthetic cyclic lipopeptide antibiotic isolated form the bacterium Streptomyces roseosporus with broad-spectrum antibiotic activity against Gram-positive bacteria. Daptomycin has a distinct mechanism of action, in which it binds to bacterial membrane and causes rapid depolarization of the cell membrane due to calcium-dependant potassium efflux; the loss of membrane potential leads to inhibition of DNA, RNA and protein synthesis, resulting in bacterial cell death. This agent does not penetrate the outer membrane of gram-negative bacteria. |
|
| Display_Name |
Daptomycin |
|
| FDA_UNII_Code |
NWQ5N31VKK |
|
| FULL_SYN |
N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone Cubicin DAPTOMYCIN Daptomycin LY146032 daptomycin |
|
| label |
Daptomycin |
|
| Legacy Concept Name |
Daptomycin |
|
| NCI_Drug_Dictionary_ID |
469015 |
|
| PDQ_Closed_Trial_Search_ID |
469015 |
|
| PDQ_Open_Trial_Search_ID |
469015 |
|
| Preferred_Name |
Daptomycin |
|
| prefixIRI |
Thesaurus:C47470 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0057144 |
|
| subClassOf |